- Report
- July 2024
- 180 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- June 2024
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- January 2022
- 60 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- April 2023
- 117 Pages
North America
From €4323EUR$4,750USD£3,706GBP
- Report
- January 2025
- 83 Pages
Vietnam
From €3185EUR$3,500USD£2,731GBP
- Report
- February 2024
- 114 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- April 2023
- 70 Pages
Canada
From €4323EUR$4,750USD£3,706GBP
- Report
- April 2023
- 85 Pages
Europe
From €4323EUR$4,750USD£3,706GBP
- Report
- April 2023
- 125 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2022
- 87 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- November 2023
- 113 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2023
- 110 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- May 2023
- 93 Pages
Global
From €3500EUR$4,120USD£3,106GBP
The Retinal Drug market is a subset of the Optical Disorders Drugs market, which focuses on treatments for diseases and disorders of the eye. Retinal drugs are used to treat a variety of conditions, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. These drugs are typically administered via intravitreal injections, which are injections directly into the eye. The Retinal Drug market is highly competitive, with a number of companies developing and marketing treatments for these conditions.
Some of the major players in the Retinal Drug market include Regeneron Pharmaceuticals, Novartis, Allergan, Bayer, and Roche. These companies have developed a range of treatments for retinal diseases, including anti-VEGF drugs, steroids, and other therapies. Show Less Read more
